Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million
New York, Aug. 10, 2022 (GLOBE NEWSWIRE) — HIGHLIGHTS:
● Insilico Medicine announces a closing of its Series D2 round, bringing the total Series D financing to $95 million, despite an uncertain market
● The Series D2 round is led by Prosperity7, the diversified growth fund of Aramco Ventures, which is an investment subsidiary of Aramco, the world’s leading integrated energy and chemicals company
● Relying on Prosperity7’s global network and generous resources, Insilico will expand its AI capabilities from drug R&D to multiple areas to support sustainable development
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a second closing of its Series D round, led b...